Association of Elevated E6 Oncoprotein With Grade of Cervical Neoplasia Using PDZ Interaction-Mediated Precipitation of E6
- 1 April 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Lower Genital Tract Disease
- Vol. 15 (2), 169-176
- https://doi.org/10.1097/lgt.0b013e3181f6c84d
Abstract
Objective. To determine the expression of human papillomavirus (HPV) type 16 E6 oncoprotein in cervical specimens of women with and without cervical intraepithelial neoplasia (CIN). Materials and Methods. Cervical specimens from 2,530 unscreened women aged 30 to 54 years from Shanxi, China, were obtained. All women were assessed by liquid-based cytology, high-risk HPV DNA tests, and colposcopy with directed biopsy and endocervical curettage as necessary. Women with abnormal cytologic results or positive HPV DNA results were recalled for colposcopy, 4-quadrant cervical biopsies, and endocervical curettage. Women with biopsy-proven CIN and cancer and a convenience sample of HC2-positive, disease-negative women were tested for the presence of HPV-16 infection via HPV-16 E6 DNA-specific polymerase chain reaction. A PDZ interaction-mediated E6 oncoprotein precipitation method followed by E6-specific Western blot was performed on specimens from women with HPV-16 infections. Associations between elevated expression of E6 oncoprotein and CIN 2 and 3 were determined using logistic regression and a reference category of CIN 1 and disease-negative. Results. A significant trend for the detection of HPV-16 E6 oncoprotein in specimen of women with proven HPV-16 infection was determined: 0% (0/12), 12.5% (1/8), 36.4% (4/11), and 42.9% (3/7) of those with negative findings, CIN 1, 2, and 3, respectively (p = .01). Compared with the category combining negative findings and CIN 1, detection of E6 oncoprotein was associated with CIN 2 (odds ratio = 10.9, p = .05) and CIN 3 (odds ratio = 14.3, p = .04). Conclusions. There is a significant association between elevated expression of E6 oncoprotein and grade of CIN. This finding seems consistent with the role played by E6 oncoprotein in carcinogenesis.Keywords
This publication has 22 references indexed in Scilit:
- A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural ChinaThe Lancet Oncology, 2008
- The Human Papillomavirus E6 Oncogene Dysregulates the Cell Cycle and Contributes to Cervical Carcinogenesis through Two Independent ActivitiesCancer Research, 2007
- Chapter 5: Updating the natural history of HPV and anogenital cancerVaccine, 2006
- Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV‐proofer and consensus PCR: A 2‐year follow‐up of women with ASCUS or LSIL pap smearInternational Journal of Cancer, 2005
- Role of the PDZ Domain-Binding Motif of the Oncoprotein E6 in the Pathogenesis of Human Papillomavirus Type 31Journal of Virology, 2004
- Mechanisms of Human Papillomavirus-Induced OncogenesisJournal of Virology, 2004
- Mechanisms of genomic instability in human cancer: Insights from studies with human papillomavirus oncoproteinsInternational Journal of Cancer, 2003
- The PDZ Ligand Domain of the Human Papillomavirus Type 16 E6 Protein Is Required for E6's Induction of Epithelial Hyperplasia In VivoJournal of Virology, 2003
- HPV E6 and MAGUK protein interactions: determination of the molecular basis for specific protein recognition and degradationOncogene, 2001
- Natural History of Cervical Intraepithelial NeoplasiaInternational Journal of Gynecological Pathology, 1993